Lugtu Isaiah C, Cheng Wen-Han, Chang Shih-Lin, Liu Shin-Huei, Lo Li-Wei, Chen Shih-Ann
Heart Rhythm Center and Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan.
Heart Institute, Chinese General Hospital and Medical Center, Metro Manila, Philippines.
Acta Cardiol Sin. 2022 May;38(3):352-361. doi: 10.6515/ACS.202205_38(3).20211130A.
Left atrial appendage (LAA) is the main source of thrombus formation, and occlusion of this structure decreases the risk of stroke in patients with atrial fibrillation.
We aimed to describe the feasibility, safety and outcomes of percutaneous LAA closure using an occluder device, and to evaluate residual LAA contrast leak detected on computed tomography (CT) imaging in patients who underwent implantation in our institution.
Consecutive patients of Taipei Veterans General Hospital who underwent percutaneous implantation of an LAA occluder (LAAO) were retrospectively collected and analyzed.
A total of 23 patients were included with a median age of 67 years (42-87) and median CHADS-VASc score of 4 (1-7). The most frequent indication for intervention was bleeding while on oral anticoagulation treatment. After a mean follow-up of 31.17 ± 25.10 months, successful device implantation was achieved in 95.7% of the patients. There was no occurrence of death, stroke, device embolization, acute ST elevation myocardial infarction, major bleeding requiring invasive treatment or blood transfusion, inguinal hematoma or major bleeding related to antiplatelet therapy. One patient had cardiac tamponade, 1 had intra-procedural thrombus formation, 1 had impingement of mitral valve leaflet, and 1 had device-related thrombosis. Of 12 patients who underwent CT post- implantation, 6 had residual contrast leak into the LAA, one third of those who had peri-device leak.
Percutaneous implantation of an LAAO appeared to be feasible with a low risk of major complications.
左心耳(LAA)是血栓形成的主要来源,封堵该结构可降低房颤患者的卒中风险。
我们旨在描述使用封堵器进行经皮左心耳封堵的可行性、安全性和结局,并评估在我们机构接受植入的患者中,计算机断层扫描(CT)成像检测到的左心耳残余造影剂渗漏情况。
回顾性收集并分析台北荣民总医院连续接受经皮左心耳封堵器(LAAO)植入的患者。
共纳入23例患者,中位年龄67岁(42 - 87岁),CHADS-VASc评分中位数为4(1 - 7)。最常见的干预指征是口服抗凝治疗时出血。平均随访31.17±25.10个月后,95.7%的患者成功植入装置。未发生死亡、卒中、装置栓塞、急性ST段抬高型心肌梗死、需要侵入性治疗或输血的大出血、腹股沟血肿或与抗血小板治疗相关的大出血。1例患者发生心包填塞,1例在手术过程中形成血栓,1例二尖瓣叶受撞击,1例发生与装置相关的血栓形成。在12例植入后接受CT检查的患者中,6例有造影剂残余渗漏至左心耳,其中三分之一有装置周围渗漏。
经皮植入左心耳封堵器似乎可行,主要并发症风险较低。